[sheet: Cover Page]

Field	Value
Report Title	Annual Compliance Report — Bilateral Advance Pricing Agreement
APA Reference Number (IRS)	[Insert IRS APA Reference Number]
APA Reference Number (BZSt)	[Insert BZSt Reference Number]
Reporting Tax Year	[Insert Tax Year, e.g., January 1, 20XX – December 31, 20XX]
Taxpayer Name (US Co-Applicant)	[Insert US Entity Legal Name]
Taxpayer EIN	[Insert EIN]
Parent Entity Name (German Applicant)	[Insert Parent Entity Legal Name]
Parent Entity Tax ID (Steuernummer)	[Insert Steuernummer]
Parent Entity VAT ID (USt-IdNr.)	[Insert USt-IdNr.]
APA Term — Prospective Period	[Insert Start Date] through [Insert End Date]
APA Rollback Period (if applicable)	[Insert Start Date] through [Insert End Date]
Total Covered Period	[Insert total covered tax years, e.g., 8 years]
Applicable Treaty	Convention between the United States and the Federal Republic of Germany for the Avoidance of Double Taxation (signed August 29, 1989, as amended by Protocol signed June 1, 2006)
Applicable Revenue Procedure	Rev. Proc. 2015-41, 2015-35 I.R.B. 263
Applicable IRC Sections	IRC §§ 482, 6662(e), 6662(h), 7121
Applicable German TP Statutes	AStG § 1; AO §§ 90(3), 162; GAufzV §§ 1–6; BsGaV
OECD Guidelines Reference	OECD Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations (2022 Edition)
Prepared By (Law Firm)	[Insert Firm Name]
Responsible Partner	[Insert Name and Title]
Billing Partner	[Insert Name and Title]
Lead Associate	[Insert Name and Title]
Date of Report Preparation	[Insert Date]
Date of Filing	[Insert Date]
Matter Number	[Insert Matter Number]

Billing Code

[sheet: Instructions]

Schedule / Sheet Name	Description	Completion Instructions	Filing Deadline Guidance
Cover Page	Identification and administrative information for the APA compliance report.	Complete all fields with the reporting tax year data. Update APA reference numbers once assigned by IRS APMA and BZSt.	File within 90 days of the due date (with extensions) for the US federal income tax return for the reporting year, per Rev. Proc. 2015-41 § 7.01.
Schedule 1 — Tested Party Financials	Income statement and balance sheet data for the tested party (US subsidiary).	Enter audited or final financial statement data for the reporting tax year. All amounts in USD. Reconcile to audited financials prepared by the independent auditor.	Include segmented data if the tested party has business lines outside the scope of the APA.
Schedule 2 — Parent Entity Financials	Consolidated income statement and key financial data for the parent entity.	Enter audited consolidated financial data in EUR. Include segment reporting for covered transactions.	Reconcile to the statutory annual report and group audit.
Schedule 3 — IC Transaction Schedule	Detailed schedule of all intercompany transactions covered by the APA.	Enter each transaction category (tangible goods, royalties, cost sharing) with EUR and USD amounts. Specify FX rates used.	Amounts must reconcile to intercompany accounts in both entities' trial balances.
Schedule 4 — PLI Calculations	Profit level indicator computations for each covered transaction.	Compute the operating margin (or other agreed PLI) for the tested party. Compare to the arm's-length range specified in the APA agreement.	Flag whether the result falls within, above, or below the agreed IQR.
Schedule 5 — Critical Assumptions	Monitoring of critical assumptions defined in the APA agreement.	Review each critical assumption and indicate whether it has been met during the reporting year. Provide narrative explanation for any deviations.	Notify IRS APMA and BZSt promptly if a critical assumption is not met, per the APA agreement terms.
Schedule 6 — Compensating Adjustments	Computation of any year-end true-up or compensating adjustments required to bring results within the arm's-length range.	If the tested party's PLI falls outside the agreed range, compute the adjustment needed to bring the result to the agreed point (e.g., median). Enter adjustment amounts and describe the mechanism.	Compensating adjustments must be reflected in amended returns or as directed by the APA agreement.
Schedule 7 — CSA Annual Report	Annual reporting for the Qualified Cost Sharing Arrangement.	Enter total qualified R&D costs, each participant's share percentage and dollar/euro amount, and any periodic adjustments. Confirm consistency with Treas. Reg. § 1.482-7.	Include reconciliation of benefit shares to projected vs. actual results.
Schedule 8 — FX Rates	Foreign exchange rate schedule used for all currency conversions in the report.	Specify the average annual rate, period-end rate, and any transaction-date or payment-date weighted average rates used for each intercompany transaction category.	Rates should be sourced from the European Central Bank or other agreed source.
Schedule 9 — Reconciliation to Audited FS	Reconciliation of tested party financial data to audited financial statements.	For each key financial line item, compare the amount used in the compliance report to the corresponding amount in the audited financial statements. Explain all differences.	Ensure reconciliation is reviewed by the engagement team prior to filing.
Schedule 10 — Certification & Signatures	Certification page for authorized officer and tax counsel signatures.	Obtain signature of an authorized officer of the US subsidiary and tax counsel confirming accuracy and completeness of the report under penalties of perjury.	Signatures must be dated on or before the filing date of the compliance report.

[sheet: Sch 1 — Tested Party Financials]

Line Item	Reporting Year (USD)	Prior Year 1 (USD)	Prior Year 2 (USD)	Notes / Source
Net Revenue (Third-Party US Sales)	[Insert Amount]	[Insert Amount]	[Insert Amount]	Reconcile to audited financials — independent auditor engagement partner
Net Revenue (Intercompany Sales, if any — non-covered)	[Insert Amount]	[Insert Amount]	[Insert Amount]	Exclude from PLI calculation if outside APA scope
Total Net Revenue	[Insert Amount]	[Insert Amount]	[Insert Amount]	Sum of third-party and non-covered IC revenue
Cost of Goods Sold (Total)	[Insert Amount]	[Insert Amount]	[Insert Amount]	Include intercompany purchases
— of which: Intercompany Purchases (Tangible Goods)	[Insert Amount]	[Insert Amount]	[Insert Amount]	Per IC transaction schedule — Sch 3
— of which: Third-Party Purchases / Direct Costs	[Insert Amount]	[Insert Amount]	[Insert Amount]
Gross Profit	[Formula: Revenue − COGS]	[Formula: Revenue − COGS]	[Formula: Revenue − COGS]
Gross Margin (%)	[Formula: Gross Profit ÷ Revenue]	[Formula: Gross Profit ÷ Revenue]	[Formula: Gross Profit ÷ Revenue]
Operating Expenses (Total)	[Insert Amount]	[Insert Amount]	[Insert Amount]
— of which: Royalty Payments to Parent (IP License)	[Insert Amount]	[Insert Amount]	[Insert Amount]	Per IC transaction schedule — Sch 3
— of which: R&D Cost-Sharing Contributions	[Insert Amount]	[Insert Amount]	[Insert Amount]	Per CSA schedule — Sch 7
— of which: Management Fee / Service Charges (IC)	[Insert Amount]	[Insert Amount]	[Insert Amount]	If applicable; indicate whether covered by APA
— of which: SG&A (excl. IC charges)	[Insert Amount]	[Insert Amount]	[Insert Amount]
— of which: Depreciation & Amortization	[Insert Amount]	[Insert Amount]	[Insert Amount]
Operating Income (EBIT)	[Formula: Gross Profit − OpEx]	[Formula: Gross Profit − OpEx]	[Formula: Gross Profit − OpEx]
Operating Margin (%)	[Formula: Operating Income ÷ Revenue]	[Formula: Operating Income ÷ Revenue]	[Formula: Operating Income ÷ Revenue]	Primary PLI — compare to APA range on Sch 4
Total Assets	[Insert Amount]	[Insert Amount]	[Insert Amount]
Net Working Capital	[Insert Amount]	[Insert Amount]	[Insert Amount]	Current Assets − Current Liabilities
Headcount (FTE)	[Insert Number]	[Insert Number]	[Insert Number]
Berry Ratio	[Formula: Gross Profit ÷ Operating Expenses]	[Formula: Gross Profit ÷ Operating Expenses]	[Formula: Gross Profit ÷ Operating Expenses]	Alternative PLI if required by APA

[sheet: Sch 2 — Parent Entity Financial]

Line Item	Reporting Year (EUR)	Prior Year 1 (EUR)	Prior Year 2 (EUR)	Notes / Source
Consolidated Revenue	[Insert Amount]	[Insert Amount]	[Insert Amount]	Per statutory annual report — reconcile to group audit
— of which: Third-Party Revenue	[Insert Amount]	[Insert Amount]	[Insert Amount]
— of which: Intercompany Revenue (Eliminated in Consolidation)	[Insert Amount]	[Insert Amount]	[Insert Amount]
Cost of Goods Sold (Consolidated)	[Insert Amount]	[Insert Amount]	[Insert Amount]
Gross Profit (Consolidated)	[Insert Amount]	[Insert Amount]	[Insert Amount]
EBITDA	[Insert Amount]	[Insert Amount]	[Insert Amount]
EBITDA Margin (%)	[Formula: EBITDA ÷ Revenue]	[Formula: EBITDA ÷ Revenue]	[Formula: EBITDA ÷ Revenue]
Operating Income (EBIT)	[Insert Amount]	[Insert Amount]	[Insert Amount]
EBIT Margin (%)	[Formula: EBIT ÷ Revenue]	[Formula: EBIT ÷ Revenue]	[Formula: EBIT ÷ Revenue]
Total R&D Expenditure	[Insert Amount]	[Insert Amount]	[Insert Amount]
Qualified CSA R&D Costs	[Insert Amount]	[Insert Amount]	[Insert Amount]	Subset of total R&D — see Sch 7
Intercompany Revenue from US Subsidiary (Tangible Goods)	[Insert Amount]	[Insert Amount]	[Insert Amount]	Reconcile to Sch 3
Intercompany Royalty Income from US Subsidiary	[Insert Amount]	[Insert Amount]	[Insert Amount]	Reconcile to Sch 3
Global Headcount	[Insert Number]	[Insert Number]	[Insert Number]
Germany Headcount	[Insert Number]	[Insert Number]	[Insert Number]

[sheet: Sch 3 — IC Transaction Schedule]

Transaction Category	Description	Direction	Amount — EUR	FX Rate Used	Amount — USD	Basis / Computation	Intercompany Agreement Reference	Notes
Tangible Goods — Wafer/Die Sales	Sale of semiconductor wafers and singulated die from parent fabrication facilities to US subsidiary	Parent → US Sub	[Insert EUR Amount]	[Insert Avg Annual EUR/USD Rate — see Sch 8]	[Formula: EUR × FX Rate]	Transfer price per Master Intercompany Supply Agreement; cost-plus markup methodology	[Insert Agreement Name, Effective Date, Amendment Date]	Reconcile to tested party COGS — Sch 1
Royalties — IP License	Running royalty for licensed semiconductor process technology and design libraries	US Sub → Parent	[Insert EUR Amount]	[Insert Payment-Date Weighted Avg EUR/USD Rate — see Sch 8]	[Formula: EUR × FX Rate]	[Insert royalty rate] × IP-attributable revenues; IP-attributable share = [Insert %] of US Sub net revenues	[Insert License Agreement Name, Effective Date]	Reconcile to tested party OpEx — Sch 1
Cost-Sharing Contributions — R&D CSA	US subsidiary's share of qualified R&D costs under Qualified Cost Sharing Arrangement	US Sub → Parent	[Insert EUR Amount]	[Insert Blended FX Rate — see Sch 8]	[Formula: EUR × FX Rate]	Total Qualified R&D Costs × [Insert CSA share %]	[Insert CSA Agreement Name, Effective Date]	See Sch 7 for detailed CSA reporting
Subtotal — Outflows from US Sub to Parent	US Sub → Parent	[Formula: Sum of Royalties + Cost-Sharing EUR amounts]	[Formula: Sum of Royalties + Cost-Sharing USD amounts]
TOTAL — Aggregate IC Flows	[Formula: Sum of all EUR amounts]	[Formula: Sum of all USD amounts]

[sheet: Sch 4 — PLI Calculations]

Covered Transaction	Transfer Pricing Method	Tested Party	Profit Level Indicator	Reporting Year PLI Result	APA Agreed IQR — Low	APA Agreed IQR — High	APA Agreed Median / Target	Within Range?	Adjustment Required?	Notes
Tangible Goods (Wafer/Die Sales)	[Insert Method, e.g., TNMM / CPM]	[Insert Tested Party Name — US Subsidiary]	Operating Margin on Net Resales	[Formula from Sch 1: Operating Income ÷ Net Revenue]	[Insert IQR Low — e.g., X.X%]	[Insert IQR High — e.g., X.X%]	[Insert Median — e.g., X.X%]	[Formula: IF result between Low and High, 'Yes', 'No']	[Formula: IF not within range, 'Yes — See Sch 6', 'No']	Number of comparables: [Insert]; data years: [Insert]; database: [Insert]
Royalties (IP License)	[Insert Method, e.g., CUT]	[Insert Tested Party Name — Licensor / Parent]	Royalty Rate (% of IP-Attributable Revenue)	[Insert contractual royalty rate]	[Insert IQR Low]	[Insert IQR High]	[Insert Median]	[Yes/No]	[Yes/No]	Number of CUT comparables: [Insert]; agreements sourced from: [Insert database]
Cost Sharing (R&D CSA)	Income Method per Treas. Reg. § 1.482-7	[Insert Participant Name — US Subsidiary]	Anticipated Benefit Share (%)	[Insert current year share %]	[Insert agreed range or fixed %]	[Insert agreed range or fixed %]	[Insert target %]	[Yes/No]	[Yes/No]	Triennial review date: [Insert]; next review: [Insert]

[sheet: Cover Page]
Field | Value
Report Title | Annual Compliance Report — Bilateral Advance Pricing Agreement
APA Reference Number (IRS) | [Insert IRS APA Reference Number]
APA Reference Number (BZSt) | [Insert BZSt Reference Number]
Reporting Tax Year | [Insert Tax Year, e.g., January 1, 20XX – December 31, 20XX]
Taxpayer Name (US Co-Applicant) | [Insert US Entity Legal Name]
Taxpayer EIN | [Insert EIN]
Parent Entity Name (German Applicant) | [Insert Parent Entity Legal Name]
Parent Entity Tax ID (Steuernummer) | [Insert Steuernummer]
Parent Entity VAT ID (USt-IdNr.) | [Insert USt-IdNr.]
APA Term — Prospective Period | [Insert Start Date] through [Insert End Date]
APA Rollback Period (if applicable) | [Insert Start Date] through [Insert End Date]
Total Covered Period | [Insert total covered tax years, e.g., 8 years]
Applicable Treaty | Convention between the United States and the Federal Republic of Germany for the Avoidance of Double Taxation (signed August 29, 1989, as amended by Protocol signed June 1, 2006)
Applicable Revenue Procedure | Rev. Proc. 2015-41, 2015-35 I.R.B. 263
Applicable IRC Sections | IRC §§ 482, 6662(e), 6662(h), 7121
Applicable German TP Statutes | AStG § 1; AO §§ 90(3), 162; GAufzV §§ 1–6; BsGaV
OECD Guidelines Reference | OECD Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations (2022 Edition)
Prepared By (Law Firm) | [Insert Firm Name]
Responsible Partner | [Insert Name and Title]
Billing Partner | [Insert Name and Title]
Lead Associate | [Insert Name and Title]
Date of Report Preparation | [Insert Date]
Date of Filing | [Insert Date]
Matter Number | [Insert Matter Number]
Billing Code | [Insert Billing Code]
[sheet: Instructions]
Schedule / Sheet Name | Description | Completion Instructions | Filing Deadline Guidance
Cover Page | Identification and administrative information for the APA compliance report. | Complete all fields with the reporting tax year data. Update APA reference numbers once assigned by IRS APMA and BZSt. | File within 90 days of the due date (with extensions) for the US federal income tax return for the reporting year, per Rev. Proc. 2015-41 § 7.01.
Schedule 1 — Tested Party Financials | Income statement and balance sheet data for the tested party (US subsidiary). | Enter audited or final financial statement data for the reporting tax year. All amounts in USD. Reconcile to audited financials prepared by the independent auditor. | Include segmented data if the tested party has business lines outside the scope of the APA.
Schedule 2 — Parent Entity Financials | Consolidated income statement and key financial data for the parent entity. | Enter audited consolidated financial data in EUR. Include segment reporting for covered transactions. | Reconcile to the statutory annual report and group audit.
Schedule 3 — IC Transaction Schedule | Detailed schedule of all intercompany transactions covered by the APA. | Enter each transaction category (tangible goods, royalties, cost sharing) with EUR and USD amounts. Specify FX rates used. | Amounts must reconcile to intercompany accounts in both entities' trial balances.
Schedule 4 — PLI Calculations | Profit level indicator computations for each covered transaction. | Compute the operating margin (or other agreed PLI) for the tested party. Compare to the arm's-length range specified in the APA agreement. | Flag whether the result falls within, above, or below the agreed IQR.
Schedule 5 — Critical Assumptions | Monitoring of critical assumptions defined in the APA agreement. | Review each critical assumption and indicate whether it has been met during the reporting year. Provide narrative explanation for any deviations. | Notify IRS APMA and BZSt promptly if a critical assumption is not met, per the APA agreement terms.
Schedule 6 — Compensating Adjustments | Computation of any year-end true-up or compensating adjustments required to bring results within the arm's-length range. | If the tested party's PLI falls outside the agreed range, compute the adjustment needed to bring the result to the agreed point (e.g., median). Enter adjustment amounts and describe the mechanism. | Compensating adjustments must be reflected in amended returns or as directed by the APA agreement.
Schedule 7 — CSA Annual Report | Annual reporting for the Qualified Cost Sharing Arrangement. | Enter total qualified R&D costs, each participant's share percentage and dollar/euro amount, and any periodic adjustments. Confirm consistency with Treas. Reg. § 1.482-7. | Include reconciliation of benefit shares to projected vs. actual results.
Schedule 8 — FX Rates | Foreign exchange rate schedule used for all currency conversions in the report. | Specify the average annual rate, period-end rate, and any transaction-date or payment-date weighted average rates used for each intercompany transaction category. | Rates should be sourced from the European Central Bank or other agreed source.
Schedule 9 — Reconciliation to Audited FS | Reconciliation of tested party financial data to audited financial statements. | For each key financial line item, compare the amount used in the compliance report to the corresponding amount in the audited financial statements. Explain all differences. | Ensure reconciliation is reviewed by the engagement team prior to filing.
Schedule 10 — Certification & Signatures | Certification page for authorized officer and tax counsel signatures. | Obtain signature of an authorized officer of the US subsidiary and tax counsel confirming accuracy and completeness of the report under penalties of perjury. | Signatures must be dated on or before the filing date of the compliance report.
[sheet: Sch 1 — Tested Party Financials]
Line Item | Reporting Year (USD) | Prior Year 1 (USD) | Prior Year 2 (USD) | Notes / Source
Net Revenue (Third-Party US Sales) | [Insert Amount] | [Insert Amount] | [Insert Amount] | Reconcile to audited financials — independent auditor engagement partner
Net Revenue (Intercompany Sales, if any — non-covered) | [Insert Amount] | [Insert Amount] | [Insert Amount] | Exclude from PLI calculation if outside APA scope
Total Net Revenue | [Insert Amount] | [Insert Amount] | [Insert Amount] | Sum of third-party and non-covered IC revenue
Cost of Goods Sold (Total) | [Insert Amount] | [Insert Amount] | [Insert Amount] | Include intercompany purchases
— of which: Intercompany Purchases (Tangible Goods) | [Insert Amount] | [Insert Amount] | [Insert Amount] | Per IC transaction schedule — Sch 3
— of which: Third-Party Purchases / Direct Costs | [Insert Amount] | [Insert Amount] | [Insert Amount]
Gross Profit | [Formula: Revenue − COGS] | [Formula: Revenue − COGS] | [Formula: Revenue − COGS]
Gross Margin (%) | [Formula: Gross Profit ÷ Revenue] | [Formula: Gross Profit ÷ Revenue] | [Formula: Gross Profit ÷ Revenue]
Operating Expenses (Total) | [Insert Amount] | [Insert Amount] | [Insert Amount]
— of which: Royalty Payments to Parent (IP License) | [Insert Amount] | [Insert Amount] | [Insert Amount] | Per IC transaction schedule — Sch 3
— of which: R&D Cost-Sharing Contributions | [Insert Amount] | [Insert Amount] | [Insert Amount] | Per CSA schedule — Sch 7
— of which: Management Fee / Service Charges (IC) | [Insert Amount] | [Insert Amount] | [Insert Amount] | If applicable; indicate whether covered by APA
— of which: SG&A (excl. IC charges) | [Insert Amount] | [Insert Amount] | [Insert Amount]
— of which: Depreciation & Amortization | [Insert Amount] | [Insert Amount] | [Insert Amount]
Operating Income (EBIT) | [Formula: Gross Profit − OpEx] | [Formula: Gross Profit − OpEx] | [Formula: Gross Profit − OpEx]
Operating Margin (%) | [Formula: Operating Income ÷ Revenue] | [Formula: Operating Income ÷ Revenue] | [Formula: Operating Income ÷ Revenue] | Primary PLI — compare to APA range on Sch 4
Total Assets | [Insert Amount] | [Insert Amount] | [Insert Amount]
Net Working Capital | [Insert Amount] | [Insert Amount] | [Insert Amount] | Current Assets − Current Liabilities
Headcount (FTE) | [Insert Number] | [Insert Number] | [Insert Number]
Berry Ratio | [Formula: Gross Profit ÷ Operating Expenses] | [Formula: Gross Profit ÷ Operating Expenses] | [Formula: Gross Profit ÷ Operating Expenses] | Alternative PLI if required by APA
[sheet: Sch 2 — Parent Entity Financial]
Line Item | Reporting Year (EUR) | Prior Year 1 (EUR) | Prior Year 2 (EUR) | Notes / Source
Consolidated Revenue | [Insert Amount] | [Insert Amount] | [Insert Amount] | Per statutory annual report — reconcile to group audit
— of which: Third-Party Revenue | [Insert Amount] | [Insert Amount] | [Insert Amount]
— of which: Intercompany Revenue (Eliminated in Consolidation) | [Insert Amount] | [Insert Amount] | [Insert Amount]
Cost of Goods Sold (Consolidated) | [Insert Amount] | [Insert Amount] | [Insert Amount]
Gross Profit (Consolidated) | [Insert Amount] | [Insert Amount] | [Insert Amount]
EBITDA | [Insert Amount] | [Insert Amount] | [Insert Amount]
EBITDA Margin (%) | [Formula: EBITDA ÷ Revenue] | [Formula: EBITDA ÷ Revenue] | [Formula: EBITDA ÷ Revenue]
Operating Income (EBIT) | [Insert Amount] | [Insert Amount] | [Insert Amount]
EBIT Margin (%) | [Formula: EBIT ÷ Revenue] | [Formula: EBIT ÷ Revenue] | [Formula: EBIT ÷ Revenue]
Total R&D Expenditure | [Insert Amount] | [Insert Amount] | [Insert Amount]
Qualified CSA R&D Costs | [Insert Amount] | [Insert Amount] | [Insert Amount] | Subset of total R&D — see Sch 7
Intercompany Revenue from US Subsidiary (Tangible Goods) | [Insert Amount] | [Insert Amount] | [Insert Amount] | Reconcile to Sch 3
Intercompany Royalty Income from US Subsidiary | [Insert Amount] | [Insert Amount] | [Insert Amount] | Reconcile to Sch 3
Global Headcount | [Insert Number] | [Insert Number] | [Insert Number]
Germany Headcount | [Insert Number] | [Insert Number] | [Insert Number]
[sheet: Sch 3 — IC Transaction Schedule]
Transaction Category | Description | Direction | Amount — EUR | FX Rate Used | Amount — USD | Basis / Computation | Intercompany Agreement Reference | Notes
Tangible Goods — Wafer/Die Sales | Sale of semiconductor wafers and singulated die from parent fabrication facilities to US subsidiary | Parent → US Sub | [Insert EUR Amount] | [Insert Avg Annual EUR/USD Rate — see Sch 8] | [Formula: EUR × FX Rate] | Transfer price per Master Intercompany Supply Agreement; cost-plus markup methodology | [Insert Agreement Name, Effective Date, Amendment Date] | Reconcile to tested party COGS — Sch 1
Royalties — IP License | Running royalty for licensed semiconductor process technology and design libraries | US Sub → Parent | [Insert EUR Amount] | [Insert Payment-Date Weighted Avg EUR/USD Rate — see Sch 8] | [Formula: EUR × FX Rate] | [Insert royalty rate] × IP-attributable revenues; IP-attributable share = [Insert %] of US Sub net revenues | [Insert License Agreement Name, Effective Date] | Reconcile to tested party OpEx — Sch 1
Cost-Sharing Contributions — R&D CSA | US subsidiary's share of qualified R&D costs under Qualified Cost Sharing Arrangement | US Sub → Parent | [Insert EUR Amount] | [Insert Blended FX Rate — see Sch 8] | [Formula: EUR × FX Rate] | Total Qualified R&D Costs × [Insert CSA share %] | [Insert CSA Agreement Name, Effective Date] | See Sch 7 for detailed CSA reporting
Subtotal — Outflows from US Sub to Parent | US Sub → Parent | [Formula: Sum of Royalties + Cost-Sharing EUR amounts] | [Formula: Sum of Royalties + Cost-Sharing USD amounts]
TOTAL — Aggregate IC Flows | [Formula: Sum of all EUR amounts] | [Formula: Sum of all USD amounts]
[sheet: Sch 4 — PLI Calculations]
Covered Transaction | Transfer Pricing Method | Tested Party | Profit Level Indicator | Reporting Year PLI Result | APA Agreed IQR — Low | APA Agreed IQR — High | APA Agreed Median / Target | Within Range? | Adjustment Required? | Notes
Tangible Goods (Wafer/Die Sales) | [Insert Method, e.g., TNMM / CPM] | [Insert Tested Party Name — US Subsidiary] | Operating Margin on Net Resales | [Formula from Sch 1: Operating Income ÷ Net Revenue] | [Insert IQR Low — e.g., X.X%] | [Insert IQR High — e.g., X.X%] | [Insert Median — e.g., X.X%] | [Formula: IF result between Low and High, 'Yes', 'No'] | [Formula: IF not within range, 'Yes — See Sch 6', 'No'] | Number of comparables: [Insert]; data years: [Insert]; database: [Insert]
Royalties (IP License) | [Insert Method, e.g., CUT] | [Insert Tested Party Name — Licensor / Parent] | Royalty Rate (% of IP-Attributable Revenue) | [Insert contractual royalty rate] | [Insert IQR Low] | [Insert IQR High] | [Insert Median] | [Yes/No] | [Yes/No] | Number of CUT comparables: [Insert]; agreements sourced from: [Insert database]
Cost Sharing (R&D CSA) | Income Method per Treas. Reg. § 1.482-7 | [Insert Participant Name — US Subsidiary] | Anticipated Benefit Share (%) | [Insert current year share %] | [Insert agreed range or fixed %] | [Insert agreed range or fixed %] | [Insert target %] | [Yes/No] | [Yes/No] | Triennial review date: [Insert]; next review: [Insert]

[sheet: Cover Page]

Record

Parties

Dates

Amounts